JMIR Hum Factors. 2026 Jan 13;13:e82916. doi: 10.2196/82916.
ABSTRACT
BACKGROUND: Women with cardiovascular disease (CVD) remain underserved due to gaps in recognition, diagnosis, and care tailored to sex-specific risks. Digital health tools have the potential to address these inequities, but many fail to reflect the distinct needs of women. In a prior review, we assessed 20 CVD apps and 22 wearables and found that only 25% (5/20) of apps and 40% (9/22) of wearables included any sex-specific content, such as hormone cycle tracking and life-stage considerations related to pregnancy or menopause. These findings confirm that current digital tools largely mirror the gender gaps seen in traditional care.
OBJECTIVE: This study aimed to define the user requirements for a CVD app designed specifically for women. We sought to explore the unmet needs and challenges faced by female patients and their clinicians that current tools fail to address, and also to identify and prioritize features that would be most valuable and feasible to implement.
METHODS: We conducted a qualitative study using semistructured interviews to explore the needs, preferences, and expectations of women living with CVD and their treating clinicians. Guided by the human-centered design framework, this work focused on the "Define" phase. A total of 20 participants in Switzerland were interviewed, including 11 women with CVD, 7 cardiologists, and 2 experts in regulatory and reimbursement. Participants were recruited through purposive sampling, and interviews were conducted online between April and July 2025. Thematic analysis was used to synthesize the data, highlighting design priorities and contextual factors relevant for developing a patient-centered and system-aware digital health tool.
RESULTS: The interviews with women living with CVD and cardiologists confirmed the consistent gaps between existing care pathways and the specific needs of female patients. Both groups highlighted the lack of early symptom recognition, insufficient sex-specific guidance, and limited tools tailored to women's lived experience. While patients prioritized personalized education, emotional support, and features that address hormonal and life-stage-specific risks, clinicians emphasized clinical use, workload integration, and actionable summaries. Success was defined experientially by patients (eg, empowerment and reduced anxiety), and operationally by clinicians (eg, earlier detection and improved adherence). Willingness to pay was moderate among both groups, with patients favoring simplicity and clinicians emphasizing workflow integration and proven clinical use.
CONCLUSIONS: These findings highlight the importance of designing an artificial intelligence-enabled CVD app for women that meaningfully integrates patient empowerment with clinical workflows. A dual-value approach is essential, offering personalized tools that address emotional and lifestyle needs for patients, while supporting clinicians with concise, actionable insights. Early reflections on regulatory and reimbursement considerations suggest that a modular, evidence-based rollout strategy would be key for long-term adoption and scale.
PMID:41529259 | DOI:10.2196/82916